<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880986/" ref="ordinalpos=3807&amp;ncbi_uid=5681666&amp;link_uid=PMC3880986" image-link="/pmc/articles/PMC3880986/figure/F4/" class="imagepopup">Fig 4.  From: 17?-Estradiol Inhibits Mesenchymal Stem Cells-Induced Human AGS Gastric Cancer Cell Mobility via Suppression of CCL5- Src/Cas/Paxillin <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>. </a></div><br /><div class="p4l_captionBody"><b> CCL-5 induces AGS cell mobility via Src signaling pathway. (A)</b> AGS cells were pretreated with vehicle, LY294002 (Akt activation inhibitor, 1μM), U0126 (ERK1/2 activation inhibitor, 1μM), SB203580 (p38 MAPK inhibitor, 1μM), SP600125 (JNK1/2 inhibitor, 1μM) or PP2 (Src inhibitor, 1μM) for 1h, and followed by recombinant CCL-5 (10 ng/ml) administration for 24h.<b> (B)</b> AGS cells were treated with these inhibitors, respectively. AGS cells were harvested and measured for cellular mobility capacity. **, p&lt;0.01 versus control (line 1); ##, p&lt;0.01 versus CCL-5 treatment (line 2) (mean ± SD, n = 3).</div></div>